{Reference Type}: Journal Article
{Title}: Pediatric Aggressive Mature B-Cell Lymphomas, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology.
{Author}: Davies K;Barth M;Armenian S;Audino AN;Barnette P;Cuglievan B;Ding H;Ford JB;Galardy PJ;Gardner R;Hanna R;Hayashi R;Kovach AE;Machnitz AJ;Maloney KW;Marks L;Page K;Reilly AF;Weinstein JL;Xavier AC;McMillian NR;Freedman-Cass DA;
{Journal}: J Natl Compr Canc Netw
{Volume}: 18
{Issue}: 8
{Year}: 08 2020
{Factor}: 12.693
{DOI}: 10.6004/jnccn.2020.0036
{Abstract}: Pediatric aggressive mature B-cell lymphomas are the most common types of non-Hodgkin lymphoma in children, and they include Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL). These diseases are highly aggressive but curable, the treatment is complex, and patients may have many complicated supportive care issues. The NCCN Guidelines for Pediatric Aggressive Mature B-Cell Lymphomas provide guidance regarding pathology and diagnosis, staging, initial treatment, disease reassessment, surveillance, therapy for relapsed/refractory disease, and supportive care for clinicians who treat sporadic pediatric BL and DLBCL.